Genmab A/S
Genmab A/S (GMAB) is a Denmark-based biotechnology company focused on developing antibody-based therapies for cancer and other serious diseases. Investors should know it operates a dual model: advancing an internal pipeline while partnering with large pharmaceutical companies to co-develop and commercialise candidates, generating revenue through milestones, royalties and licence fees. The company’s strengths include proprietary antibody platforms and experience progressing programmes through late‑stage development, which can enhance the value of partnered assets. That said, biotech investing carries higher risk — clinical setbacks, regulatory decisions, patent disputes and market competition can materially affect outlook and share price. Genmab’s market capitalisation (about $19.13bn) reflects significant investor confidence, but future returns are uncertain. Investors may watch clinical readouts, partnership updates and cash runway. This is general educational information and not personalised financial advice; consider your own suitability and consult a professional if needed.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Genmab's stock with a target price of $39.2, indicating strong growth potential.
Financial Health
Genmab is achieving strong sales and profits, with significant cash generation and high profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring GMAB
Next-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: July 3, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical readouts and regulatory decisions can be major value drivers, though trial outcomes are uncertain and timelines can shift.
Partner-led Revenue
Collaborations with large pharmaceutical firms provide milestone and royalty income, offering diversification but depending on partner execution.
Proprietary Platforms
Genmab’s antibody technologies can speed discovery and create long-term opportunity, while commercial success still depends on competition and execution.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
